Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) Anadys' belief that ANA773 holds promise as a potential replacement for injectable interferon products in HCV therapy; (ii) Anadys' ability to seek and obtain partnership opportunities to further the development of ANA773; (iii) the ability to create well-tolerated, all oral combination regimens to treat hepatitis C; (iv) the potential to further improve response by combining ANA773 with other agents, including ribavirin; and (v) the potential for alternative dosing schedules to further improve pharmacological response to TLR7 activation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA773 will not have unforeseen safety issues or will have favorable results in future clinical studies. Furthermore, Anadys cannot provide any assurances that it will be able to obtain a partnership around ANA773 or that the development of the program will be continued. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 AmerisourceBergen’s ... Canadian specialty market, is now providing U.S. manufacturers ... new 160,000-square-foot distribution center coupled with its fully-licensed ... healthcare industry has historically been difficult for smaller ... government regulation complexities. As a result of these ...
(Date:9/23/2014)... 23, 2014 The print component of ... Metro, with a circulation of approximately 327,720 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with Michael Landsberg, host of TSN’s Off ...
(Date:9/23/2014)... WASHINGTON, Sept. 23, 2014 Antibiotics revolutionized health ... bacteria that once killed thousands of people. But ... strains of antibiotic-resistant bacteria are popping up more ... the current shortage of new antibiotics and discusses ... answers the question: Why should you finish your ...
(Date:9/23/2014)... Ind. -- Contrary to what is often assumed about ... new study from The Kinsey Institute has found that ... are sexually active as often as singles without children ... children. , The study, "Dating and Sexual Behavior Among ... was published online in the Journal of Sex ...
(Date:9/23/2014)... SC (PRWEB) September 23, 2014 On September ... by Keith Simmons for an episode. Simmons is the founder ... Deierlein believed the audience would like to know. At the ... get the idea to start this magazine?” Simmons replied by ... advertising sales person. In 2005, I quit that and decided ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... scientists have been chosen from a highly competitive field ... Merck Sharp & Dohme and Advance to boost the ... Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr ... have been selected as joint winners of the 2008 ...
... important international relationships is top of the agenda ... Dr Raisa Monteiro, when she meets with leading ... One of two Australian life scientists chosen from ... prestigious 2008 Advancing BioBusiness Award, Russian-born Dr Monteiro ...
... anemia in expectant mothers and spinal birth defects in newborns, the ... has now been shown to blunt the damaging effects of heart ... In a new study, an international team of heart experts at ... daily of folate, also known as folic acid or vitamin B9, ...
... Solution for ... Employers, ... believe the future of managing health care costs lies in,helping their ... Seventh Annual Tri-State Area Employee,Benefit Survey., Cowden Associates, the region,s ...
... US$1.75 million of new available funds -, ... Inc. (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, ... under the agreement to repay US$1.75 million of ... Laurus Master Funds),in common shares., The conversion ...
... ROLLA, Mo., March 27 While today,s shaky economy ... has been an,exception. In fact, there is currently a ... positions. Furthermore, according to the latest,projections from the U.S. ... replacement nurses will be needed by 2014 -- and ...
Cached Medicine News:Health News:Rising Australian biotech stars set to connect on the world stage 2Health News:DendriMed scientist seeks to fast-track success 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 2Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 3Health News:Folate scores a win in animal studies: Brief, high doses of B vitamin blunt damage from heart attack 4Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 2Health News:Survey Highlights Ongoing Shift To Wellness to Manage Health Care Costs 3Health News:Bioniche Converts a Portion of its Debt to Equity 2Health News:NurseAuction.com Aims to Alleviate Nurse Shortage with Online Nurse Bidding 2
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
Medicine Products: